Asimov Press: “Recombinant DNA technologies were invented in the 1970s. Gene-editing methods, polymerase chain reaction, and the first human drug made from engineered microbes all debuted in the 1980s. A human chromosome was sequenced in the 1990s, a few years after Dolly the Sheep was cloned. A first draft of the human genome was completed in 2003. CRISPR gene-editing was invented in 2012 and applied to human embryos soon after. At least six CAR-T cancer therapies have now garnered F.D.A. approval, and chick-culling technologies could save millions of male chicks from shredders each year. The bioeconomy today accounts for 5 percent of U.S. GDP, more than mining or construction. With most of these advancements taking place in the last 50 years, we expect even more to happen in the next 50. There is an urgent need to understand and safely guide biological progress into the future.”
Deepu Talla: “GenAI’s impact will be transformative across robotics from simulation to design and more. Simulation: Models will be able to accelerate simulation development, bridging the gaps between 3D technical artists and developers, by building scenes, constructing environments and generating assets. These GenAI assets will see increased use for synthetic data generation, robot skills training and software testing. Multimodal AI: Transformer-based models will improve the ability of robots to better understand the world around them, allowing them to work in more environments and complete complex tasks. Robot (re)programming: Greater ability to define tasks and functions in simple language to make robots more general/multipurpose. Design: Novel mechanical designs for better efficiency — for example, end effectors.”
Ben Thompson: “Google, at its core, has always been much more like Apple than Microsoft. It wants to control everything, it just needs to do it legally; that the best manifestation of AI is almost certainly dependent on a fully integrated (and thus fully seamless) experience means that the company can both control everything and, if it pulls this gambit off, serve everyone. The problem is that the risks are massive: Google would not only be risking search revenue, it would also estrange its OEM partners, all while spending astronomical amounts of money. The attempt to be the one AI Assistant that everyone uses — and pays for — is the polar opposite of the conservative approach the company has taken to the Google Aggregator Paradox. Paying for defaults and buying off competitors is the strategy of a company seeking to protect what it has; spending on a bold assault on the most dominant company in tech is to risk it all. And yet, to simply continue on the current path, folding AI into its current products and selling it via Google Cloud, is a risk of another sort… Google could build the AI to win it all. It’s not guaranteed they would succeed, but the opportunity is there if they want to go for it. That is the path that would be in the nature of the Google that conquered the web twenty years ago, the Google that saw advertising as the easiest way to monetize what was an unbridled pursuit of self-contained technological capability.”
NYTimes: “Researchers define biological age as “the accumulation of damage we can measure in our body,” said Dr. Andrea Britta Maier, co-director of the Centre for Healthy Longevity at the National University of Singapore. That damage comes from natural aging, as well as from our environment and behaviors…A major advance came in 2013 when Steve Horvath, a professor of human genetics and biostatistics at the University of California, Los Angeles, proposed using a “clock” based on the emerging field of epigenetics. Over the course of our lives, our DNA accumulates molecular changes that turn on and off various genes. Dr. Horvath analyzed these changes in thousands of people and developed an algorithm to determine how they correlate with age. These changes happen naturally as we get older, said Jesse Poganik, an instructor at Harvard Medical School who researches biological aging; they can also be sped up by behaviors that affect health, like smoking and excessive alcohol consumption. As a result, estimates of biological age have been shown to be associated with things like life expectancy and health, he said.”
FT Person of the Year: Lars Fruergaard Jørgensen of Novo Nordisk. “The Danish company’s drugs for obesity could have a profound impact on healthcare, society and our relationship with food…[It] is the company behind the first game-changing treatments that are used for obesity: Wegovy and Ozempic. Before these drugs, the only truly effective treatment was bariatric surgery, which is expensive and sometimes risky. Now there is a simple injection. A safe and readily available treatment for obesity could have a huge impact on human health, while also generating savings on treating other diseases. Obesity will affect an estimated 1bn people by 2030 — with all the associated impact that has on rates of diabetes, heart disease and mobility. In the US alone, the economy loses up to $30bn a year in sick days due to the condition, according to research from Cornell. And it is not just obesity: there is now good evidence to suggest the company’s drugs could also help prevent heart attacks and there is even some hope they could be used to treat Alzheimer’s by reducing inflammation in the brain.”
